Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have received an average recommendation of “Hold” from the five research firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $6.3333.

A number of research firms have recently commented on ATOS. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, October 8th. Zacks Research downgraded Atossa Genetics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Finally, Ascendiant Capital Markets boosted their price objective on Atossa Genetics from $7.75 to $8.00 and gave the company a “buy” rating in a research report on Monday, December 8th.

Hedge Funds Weigh In On Atossa Genetics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Atossa Genetics by 4.2% in the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after purchasing an additional 245,717 shares during the period. Ameriprise Financial Inc. acquired a new stake in Atossa Genetics in the 2nd quarter worth about $2,468,000. Jane Street Group LLC purchased a new stake in Atossa Genetics during the 2nd quarter worth approximately $381,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Atossa Genetics by 40.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company’s stock valued at $284,000 after acquiring an additional 120,934 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in shares of Atossa Genetics by 357.4% in the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after acquiring an additional 325,340 shares in the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

Atossa Genetics Price Performance

NASDAQ:ATOS opened at $0.66 on Monday. The company has a 50 day moving average price of $0.80 and a 200-day moving average price of $0.84. Atossa Genetics has a 1-year low of $0.55 and a 1-year high of $1.29. The firm has a market cap of $85.11 million, a price-to-earnings ratio of -2.75 and a beta of 0.95.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). On average, sell-side analysts anticipate that Atossa Genetics will post -0.22 earnings per share for the current fiscal year.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.